Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Imad Treish (), Abeer Al Rabayah (), Saad Jaddoua and Haitham Tuffaha ()
Additional contact information
Imad Treish: Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA)
Abeer Al Rabayah: Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA)
Saad Jaddoua: Department of Pharmacy, Center for Drug Policy and Technology Assessment (CDPTA)
Haitham Tuffaha: The University of Queensland

PharmacoEconomics - Open, 2022, vol. 6, issue 2, No 1, 137-145

Abstract: Abstract Rising prices of novel cancer medications are increasing the economic burden from cancer in Jordan, risking the ability of cancer patients to access lifesaving and life-extending treatments. Furthermore, in the absence of a national health technology assessment (HTA) framework, medication prices in Jordan are set based on manufacturers’ pricing considerations and not a value proposition. In response to these challenges, King Hussein Cancer Center (KHCC), the de facto national cancer institute, developed a first-in-country, cancer-specific, cost-effectiveness threshold (CET) to aid institutional decision makers in approving only cost-effective medications. Over the past 10 years, cost-effectiveness analyses based on this CET have led to the introduction of > 70% of requested novel cancer medications after manufacturers agreed to lower prices, beyond registration prices, to meet the CET. Future work is warranted to empirically derive a CET for Jordan to better guide reimbursement decisions.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-021-00293-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:2:d:10.1007_s41669-021-00293-4

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-021-00293-4

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().